Acesso livre
Acesso livre

Infectologia

Estudo randomizado | Tratamento precoce de pacientes ambulatoriais com plasma convalescente reduz o risco de internação para pacientes com Covid-19.

1 Abr, 2022 | 12:30h

Early Outpatient Treatment for Covid-19 with Convalescent Plasma – New England Journal of Medicine

Comentários:

Study finds convalescent plasma can be effective early COVID-19 therapy – Johns Hopkins University School of Medicine

Early Use of High-Titer Plasma Reduced COVID Hospitalizations— Randomized trial that influenced indication shows benefits in a mostly unvaccinated population – MedPage Today (necessário cadastro gratuito)

 

Comentário no Twitter

 

Estudo de caso-controle | Em crianças de 5 a 11 anos de idade, a vacina da Pfizer mostrou efetividade de 68% contra internação causada pela variante Ômicron.

1 Abr, 2022 | 12:29h

BNT162b2 Protection against the Omicron Variant in Children and Adolescents – New England Journal of Medicine

Comentário: COVID vaccination of children age 5-11 cut omicron hospitalizations by 68% – Children’s Hospital Boston

Conteúdo relacionado: [Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

 

Comentário no Twitter

 

Risco de reinfecções por SARS-CoV-2 em crianças: um estudo de vigilância nacional prospectiva na Inglaterra.

1 Abr, 2022 | 12:24h

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England – The Lancet Child & Adolescent Health

Comentário convidado: Importance of understanding the reinfection risk of COVID-19 in children – The Lancet Child & Adolescent Health

 

Comentário no Twitter

 

Uma revisão narrativa sobre a abordagem do uso de antibióticos em pacientes ventilados apresentando organismos multirresistentes em amostras respiratórias – tratar ou não tratar?

1 Abr, 2022 | 12:22h

A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samples—To Treat or Not to Treat? That Is the Question – Antibiotics

 

Comentário no Twitter

 

Nature Outlook | Hepatite B.

1 Abr, 2022 | 12:10h

Página principal: Nature Outlook: Hepatitis B

Hepatitis B

Closing in on a cure for hepatitis B

Developing a cure for chronic hepatitis B requires a fresh approach

How to stop mother-to-child transmission of hepatitis B

Simplify access to hepatitis B care

Destigmatizing hepatitis B

Facing the challenge of eliminating hepatitis B

The global fight against hepatitis B is benefitting some parts of the world more than others

Africa’s struggle with hepatitis B

Why hepatitis B hits Aboriginal Australians especially hard

Hepatitis B and the liver cancer endgame

Research round-up: hepatitis B

Charting a new frontier in chronic hepatitis B research to improve lives worldwide

Addressing the unmet need for a functional cure for chronic hepatitis B

[Preprint] Estudo de coorte retrospectiva | 2º reforço de vacina e mortalidade por Covid-19 em adultos de 60 a 100 anos de idade.

31 Mar, 2022 | 13:44h

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square

Comentários:

Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical

EUA aprovam 2ª dose de reforço contra Covid-19 para pessoas de 50 anos de idade ou mais e indivíduos imunocomprometidos.

31 Mar, 2022 | 13:41h

U.S. approves second Covid-19 booster for people 50 and older – STAT

FDA OKs second COVID booster shot for older Americans – CIDRAP

Ver diretriz: Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals – U.S. Food & Drug Administration

Estudo de coorte | Desfechos de curto prazo da monoterapia com corticosteroide na síndrome inflamatória multissistêmica em crianças.

31 Mar, 2022 | 13:40h

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children – JAMA Pediatrics

 

Comentário no Twitter

 

Estudo RECOVERY – 2 anos.

31 Mar, 2022 | 13:38h

The RECOVERY Trial – two years on – University of Oxford

Conteúdos relacionados:

How the UK found the first effective Covid-19 treatment — and saved a million lives (about the RECOVERY trial and the effects of Dexamethasone)

Covid: The London bus trip that saved maybe a million lives (about the creation of the RECOVERY Trial)

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 – Recovery Trial

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

RECOVERY Trial: Aspirin as an add-on therapy did not reduce mortality in patients hospitalized with COVID-19.

RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes

RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.

RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19

Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

 

Comentário no Twitter

 

Relato de caso | Os danos da antibioticoprofilaxia pós-operatória.

31 Mar, 2022 | 13:36h

The Harms of Postoperative Antibiotic Prophylaxis: A Teachable Moment – JAMA Internal Medicine (gratuito por tempo limitado)

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.